Group B streptococcal infection future or investigational therapies
|
Group B Streptococcal Infection Microchapters |
|
Differentiating Group B Streptococcal Infection from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Group B streptococcal infection future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Group B streptococcal infection future or investigational therapies |
|
FDA on Group B streptococcal infection future or investigational therapies |
|
CDC on Group B streptococcal infection future or investigational therapies |
|
Group B streptococcal infection future or investigational therapies in the news |
|
Blogs on Group B streptococcal infection future or investigational therapies |
|
Directions to Hospitals Treating Group B streptococcal infection |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]
Overview
There is no Group B streptococcus (GBS) vaccine currently available to help mothers protect their newborns from GBS disease. Researchers are working on developing a vaccine, which may become available one day in the future. Phase I and II clinical trials among healthy, nonpregnant adults of monovalent polysaccharide-protein conjugate vaccines of GBS disease-associated types have shown these vaccines to be well tolerated and immunogenic. A recent, double-blind randomized trial of a conjugate vaccine against GBS serotype III among nonpregnant women of reproductive age found a significant delay in acquisition of colonization with the vaccine-serotype among vaccine recipients.[1]